Nivalis Therapeutics, which is developing a complementary small molecule therapy for cystic fibrosis, announced terms for its IPO on Wednesday.
The Boulder, CO-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Nivalis Therapeutics would command a fully diluted market value of $200 million.
Nivalis Therapeutics, which was founded in 2007, plans to list on the NASDAQ under the symbol NVLS. Cowen & Company and Stifel are the joint bookrunners on the deal. It is expected to price during the week of June 15, 2015.
